Serum biomarkers such as Cancer Antigen 15-3 (CA 15-3) or Carcinoembryonic Antigen (CEA) are applied mainly for monitoring treatment response in patients with advanced disease4 and do not provide adequate answers in terms of early diagnosis, prognosis or subtyping of breast cancer. Here, CEACAM5 is linked to breast carcinoma.